148 related articles for article (PubMed ID: 32558591)
1. Imiquimod 5% Cream as Adjuvant Therapy in BCC Treatment Located at High-Risk Regions.
Cengiz FP; Kelahmetoglu O; Emiroglu N; Onsun N
J Cutan Med Surg; 2020; 24(6):640-641. PubMed ID: 32558591
[No Abstract] [Full Text] [Related]
2. Successful treatment of multifocal pigmented basal cell carcinomas with the application of topical 5% imiquimod cream.
Plachouri KM; Balasis S; Mallioris AF; Koumoundourou D; Georgiou S
Dermatol Ther; 2018 Sep; 31(5):e12685. PubMed ID: 30133929
[TBL] [Abstract][Full Text] [Related]
3. Topical imiquimod as a neo-adjuvant chemotherapy for cartilage salvage in the treatment of nodular basal cell carcinomas of the head and neck.
Singh S; Rajan MB; Bhardwaj A
Indian J Dermatol Venereol Leprol; 2021; 87(3):452-454. PubMed ID: 33871202
[No Abstract] [Full Text] [Related]
4. Insight into imiquimod skin permeation and increased delivery using microneedle pre-treatment.
Al-Mayahy MH; Sabri AH; Rutland CS; Holmes A; McKenna J; Marlow M; Scurr DJ
Eur J Pharm Biopharm; 2019 Jun; 139():33-43. PubMed ID: 30771455
[TBL] [Abstract][Full Text] [Related]
5. What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial.
Tinelli M; Ozolins M; Bath-Hextall F; Williams HC
BMC Dermatol; 2012 Oct; 12():19. PubMed ID: 23035730
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial.
Jia HX; He YL
J Dermatolog Treat; 2020 Dec; 31(8):831-838. PubMed ID: 31294669
[No Abstract] [Full Text] [Related]
7. A meta-analysis of treatment effects of imiquimod for basal cell carcinoma.
Li MY; Zhang XP; Duan XB; Cao XC; Zhao HJ
J Cosmet Dermatol; 2020 Jan; 19(1):218-225. PubMed ID: 31692232
[TBL] [Abstract][Full Text] [Related]
8. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment of daylight photodynamic therapy and imiquimod 5% cream for the treatment of superficial basal cell carcinoma on sun exposed areas.
Paolino G; Didona D; Scarnò M; Tallarico M; Cantoresi F; Calvieri S; Mercuri SR; Piccolo D; Bottoni U; Kyriakou A; Cantisani C
Dermatol Ther; 2019 Mar; 32(2):e12788. PubMed ID: 30499211
[No Abstract] [Full Text] [Related]
11. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
[TBL] [Abstract][Full Text] [Related]
13. Response of basal cell carcinoma to imiquimod was associated with the Gli1 : Gli3 expression ratio.
Kanzaki A; Kato Y; Kariya T; Kanda Y; Shirai K; Arai T; Tsuboi R
Br J Dermatol; 2018 Dec; 179(6):1406-1407. PubMed ID: 30019418
[No Abstract] [Full Text] [Related]
14. Severe balanoposthitis secondary to treatment with topical imiquimod.
Elizalde-Benito FX; Elizalde-Benito AG; Urra-Palos M; Quintana-Martínez I; Elizalde-Amatria AG
Arch Esp Urol; 2019 Dec; 72(10):1056-1057. PubMed ID: 31823857
[No Abstract] [Full Text] [Related]
15. Sequential Treatment of Superficial Basal Cell Carcinomas With Topical Methyl Aminolevulinate Photodynamic Therapy and Imiquimod 5% Cream: A Retrospective Study of Clinical and Cosmetic Outcomes.
Logan IT; Kulakov EL; Perrett CM
Dermatol Surg; 2020 Oct; 46(10):1272-1278. PubMed ID: 32011386
[TBL] [Abstract][Full Text] [Related]
16. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
Love WE; Bernhard JD; Bordeaux JS
Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
[TBL] [Abstract][Full Text] [Related]
17. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
Ruiz-Villaverde R; Sánchez-Cano D; Burkhardt-Pérez P
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):828-31. PubMed ID: 19646136
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids.
Prokosch V; Thanos S; Spaniol K; Stupp T
Graefes Arch Clin Exp Ophthalmol; 2011 Jan; 249(1):121-5. PubMed ID: 20886224
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
Drehs MM; Cook-Bolden F; Tanzi EL; Weinberg JM
Dermatol Surg; 2002 May; 28(5):427-9. PubMed ID: 12030878
[TBL] [Abstract][Full Text] [Related]
20. Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial.
Sinx KAE; Nelemans PJ; Kelleners-Smeets NWJ; Winnepenninckx VJL; Arits AHMM; Mosterd K
J Am Acad Dermatol; 2020 Aug; 83(2):469-476. PubMed ID: 32320773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
